Home » Stocks » ACHL

Achilles Therapeutics plc (ACHL)

Stock Price: $13.78 USD -0.73 (-5.03%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
After-hours: $13.60 -0.18 (-1.31%) Apr 9, 5:36 PM
Market Cap 559.77M
Revenue (ttm) n/a
Net Income (ttm) -33.20M
Shares Out 40.62M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 9
Last Price $13.78
Previous Close $14.51
Change ($) -0.73
Change (%) -5.03%
Day's Open 14.28
Day's Range 13.72 - 15.11
Day's Volume 207,201
52-Week Range 13.72 - 18.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...

3 days ago - GlobeNewsWire

Achilles Therapeutics plc (NASDAQ: ACHL) announced the pricing of its IPO on the Nasdaq that will raise US$175.5mln (£127.8mln). The clinical-stage biopharma, which is developing precision T cell therap...

1 week ago - Proactive Investors

LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...

1 week ago - GlobeNewsWire

Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, filed on Monday with the SEC to raise up to $100 million in an initial public offering.

1 month ago - NASDAQ

Achilles Therapeutics plc has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About ACHL

Achilles Therapeutics is a clinical stage immuno-oncology biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumors. Our platform enables us to identify mutations formed early in the development of a cancer that give rise to antigens. We refer to this novel class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, we have developed a proprietary bioinformatic platform called PELEUS. This platform employs sophisticated statistical algorithms trained on the uniqu... [Read more...]

Industry
Biological Products
IPO Date
Mar 31, 2021
CEO
Iraj Ali, Ph.D.
Employees
153
Stock Exchange
NASDAQ
Ticker Symbol
ACHL
Full Company Profile

Financial Performance

Financial Statements